- Previous Close
14.18 - Open
13.02 - Bid 12.76 x --
- Ask 13.62 x --
- Day's Range
11.90 - 13.98 - 52 Week Range
10.57 - 47.25 - Volume
1,069 - Avg. Volume
7,042 - Market Cap (intraday)
19.204M - Beta (5Y Monthly) 2.13
- PE Ratio (TTM)
0.09 - EPS (TTM)
148.09 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Fluicell AB (publ) operates as a life science company, provides platforms and research solutions for bioprinting and single-cell biology. The company offers BIOPEN, a microfluidic platform for high-precision single-cell solution delivery that enables to control the cell microenvironment without moving or disturbing the cells; Biozone 6 that generate dose-response curves or study the effects of multiple drug compounds; and Dynaflow Resolve system, an ion channel screening platform, which allows to record various ion channel current in patch-clamp recording configuration. It also provides Biopixlar, a 3D single-cell bioprinting platform that enables high cell viability and cell-to-cell communication; and Biopixlar AER, an easy-to-use 3D bioprinting platform that fits into your fume hood or biosafety cabinet. The company also offers accessory and consumable products for bioprinting and single-cell biology. The company was incorporated in 2012 and is based in Mölndal, Sweden.
www.fluicell.comRecent News: FLUI.ST
View MorePerformance Overview: FLUI.ST
Trailing total returns as of 4/3/2025, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: FLUI.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: FLUI.ST
View MoreValuation Measures
Market Cap
19.48M
Enterprise Value
-2.21M
Trailing P/E
0.10
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
12.47
Price/Book (mrq)
0.95
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-289.98%
Return on Assets (ttm)
-56.83%
Return on Equity (ttm)
-157.80%
Revenue (ttm)
5.35M
Net Income Avi to Common (ttm)
-15.51M
Diluted EPS (ttm)
148.09
Balance Sheet and Cash Flow
Total Cash (mrq)
15.92M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-15.83M